top of page

Takeda certified as Great Place to Work® in India for second year in a row

Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been certified as a Great Place To Work® in India (March 2023 – March 2024). This certification has been awarded second time in a row to Takeda. The acknowledgement serves as evidence of the exceptional culture that the organization has nurtured by prioritizing the key values of Integrity, Fairness, Honesty and Perseverance.

Commenting on the recognition, Mrs Serina Fischer, General Manager, Takeda Biopharmaceuticals India Private Limited said, “This is the second year we have been recognized; it’s an acknowledgement of our unwavering commitment to creating a work culture where our employees feel heard, included, valued and empowered. We remain steadfast in providing a fair, equitable, and non-discriminatory workplace where our people can be their own true selves and contribute meaningfully to solving complex challenges as we seek to improve healthcare in India. We also understand that growth for our people means growth for our business, and we are constantly improving our ways of working to ensure agility and provide our employees the space to share and implement innovative ideas while developing their skill sets. What we do and how we do it has the power to influence our culture. We, therefore, encourage our employees to adopt Takeda Leadership Behaviors to foster an environment that enables us to fulfill our purpose while always remaining committed to our value system.”

Adding to the same, Mr. Anoop Kamat, Head of Human Resources, Takeda Biopharmaceuticals India Private Limited said, “At Takeda, we have always placed a strong emphasis on our employees and their well-being. This achievement is a testament of our commitment to fostering a workplace culture of inclusivity and growth. As an equal opportunity employer, we have strived to nurture our employees’ talents by providing them with the necessary support to help them reach their full potential as we work towards fulfilling our vision for India. We remain committed to creating an environment where all our employees feel welcomed, understood, and encouraged.”

Great Place To Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting, and insights they need to make strategic people decisions. The Institute serves businesses, non-profits and government agencies in more than 60 countries and has conducted pioneering research on the characteristics of great workplaces for over three decades.

In India, the institute partners with more than 1400 organizations annually across over 22 industries to help them build High-Trust, High-PerformanceCultures designed to deliver sustained business results. Hundreds of CEOs and CXOs from India Inc. are part of the great place community that is committed to the vision of making India a great place to work for all.

The Institute’s research shows that great workplaces are characterized by great leadership, consistent employee experience, and sustainable financial performance. These organizations can deliver a consistent experience to all their employees irrespective of their role, gender, tenure, or level. Their leaders believe in the vision of creating and sustaining a great place to work for all and role models being for all leaders.

About Takeda Biopharmaceuticals India Private Limited

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit


bottom of page